Holen Sie sich die Stockscreener-App
111.12
2.40%
2.60
Schlusskurs vom Vortag:
$108.52
Offen:
$106.61
24-Stunden-Volumen:
265.22K
Relative Volume:
1.48
Marktkapitalisierung:
$744.40M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.99M
KGV:
-53.77
EPS:
-2.0665
Netto-Cashflow:
$-10.01M
1W Leistung:
+4.24%
1M Leistung:
+72.57%
6M Leistung:
+58.74%
1J Leistung:
+135.17%
1-Tages-Spanne:
$104.00
$111.94
1-Wochen-Bereich:
$97.93
$111.94
52-Wochen-Spanne:
$29.18
$112.57
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Firmenname
Monopar Therapeutics Inc
Sektor
Branche
Telefon
(847) 388-0349
Adresse
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
111.12 | 726.98M | 0 | -14.99M | -10.01M | -2.0665 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-11-14 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-11-10 | Eingeleitet | Leerink Partners | Outperform |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-09-09 | Eingeleitet | BTIG Research | Buy |
| 2025-09-03 | Eingeleitet | Oppenheimer | Outperform |
| 2025-09-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-08-26 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-06-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-19 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-01-10 | Eingeleitet | Piper Sandler | Overweight |
| 2024-10-11 | Eingeleitet | Rodman & Renshaw | Buy |
| 2021-01-28 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Monopar Therapeutics Inc Aktie (MNPR) Neueste Nachrichten
Monopar: A Rare Disease Asset With Heavy-Metal Upside (Initiating Buy) - Seeking Alpha
Cantor Fitzgerald reiterates Monopar stock Overweight rating at $109 By Investing.com - Investing.com South Africa
Monopar Therapeutics stock trades near $98.20–$111.48 range as buyer strength dominates session - Traders Union
Will Monopar Therapeutics stock regain momentum as buyers support the ongoing rally? - Traders Union
Price to sales forward of Monopar Therapeutics Inc – DUS:1IY0 - TradingView
Monopar Therapeutics stock drops almost 4% after earnings beat followed by downgrade to 'sell' - Traders Union
MNPR Q1 2026 Earnings: EPS Beats Estimates by 46% as Pipeline AdvancesEarnings Acceleration Picks - dars.gov.et
(MNPR) Movement as an Input in Quant Signal Sets - Stock Traders Daily
MNPR (MNPR): Arthur Klausner files Form 144/A to sell 5,000 shares - Stock Titan
Biotech Stocks At 52-Week Highs: TRAX, BBIO, MNPR, TXG, MPLT - RTTNews
Monopar Therapeutics shares gain about 9.5% after immediate support holds above $100.45 - Traders Union
What's behind Monopar Therapeutics's latest 11.6% stock surge? - Traders Union
Form 144 Monopar Therapeutics Inc. For: 7 July By Investing.com - Investing.com Nigeria
[144] Monopar Therapeutics SEC Filing - Stock Titan
MNPR stock. Monopar Therapeutics stays tied to its clinical pipeline. - ad-hoc-news.de
Enterprise value to EBIT forward of Monopar Therapeutics Inc. – NASDAQ:MNPR - TradingView
Monopar Therapeutics: ALXN1840's Bull Case Has Improved (NASDAQ:MNPR) - Seeking Alpha
Form 4 Monopar Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Monopar Therapeutics (MNPR) CFO nets shares from RSU vesting and tax withholding - Stock Titan
Monopar Therapeutics (MNPR) CEO nets shares after RSU vesting and tax withholding - Stock Titan
Monopar Therapeutics (MNPR) COO gains stock via RSU vesting and tax withholding - Stock Titan
Liquidity Mapping Around (MNPR) Price Events - Stock Traders Daily
Monopar Therapeutics price target raised to $117 from $104 at BTIG - TipRanks
BTIG Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $117 - Moomoo
MNPR Q1 2026 Earnings: Significant EPS Beat Highlights Progress in Clinical PipelineDiluted EPS Report - dars.gov.et
Form 4 Monopar Therapeutics Inc For: 30 June By Investing.com - Investing.com Nigeria
MNPR Maintained by BTIG -- Price Target Raised to $117 - GuruFocus
Monopar Therapeutics (MNPR) director granted 1,284 stock options - Stock Titan
Monopar Therapeutics (MNPR) director Nicole Sweeny files initial Form 3 - Stock Titan
Monopar gets rare pediatric disease tag for Wilson treatment - Investing.com UK
Monopar Therapeutics (MNPR) Receives FDA Rare Pediatric Disease Designation - GuruFocus
Monopar Therapeutics Inc. Granted FDA Rare Pediatric Disease Designation – Official SEC 8-K Filing June 30, 2026 - Minichart
BTIG Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $117 - Moomoo
Monopar Wins FDA Rare Pediatric Disease Designation - TipRanks
Monopar stock jumps after FDA rare pediatric disease tag By Investing.com - Investing.com India
Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease - The Manila Times
FDA grants Rare Pediatric Disease designation to Monopar (MNPR) Wilson disease drug ALXN1840 - Stock Titan
FDA rare pediatric disease tag could speed ALXN1840’s path for Wilson disease - Stock Titan
BTIG raises Monopar Therapeutics price target on regulatory outlook - Investing.com
BTIG raises Monopar Therapeutics price target on regulatory outlook By Investing.com - Investing.com Canada
+8.47% for Monopar Therapeutics stock as buyers push price above key averages - Traders Union
Monopar Therapeutics Inc Actuals & Estimates (NASDAQ:MNPR) - TradingView
H.C. Wainwright reiterates Monopar stock rating on trial data By Investing.com - Investing.com India
Companies Like Monopar Therapeutics (NASDAQ:MNPR) Can Afford To Invest In Growth - Moomoo
Monopar Therapeutics Inc.(NasdaqCM: MNPR) added to Russell 2000 Value Benchmark - marketscreener.com
H.C. Wainwright reiterates Monopar stock rating on trial data - Investing.com UK
Monopar Therapeutics Inc.(NasdaqCM:MNPR) added to Russell Microcap Value Benchmark Index - marketscreener.com
MNPR Reiterates by HC Wainwright & Co. -- Price Target Maintained at $105 - GuruFocus
Monopar Therapeutics Insiders Make Handsome Sum Selling Stock At US$67.15 Per Share - simplywall.st
Price to earnings forward of Monopar Therapeutics Inc. – NASDAQ:MNPR - TradingView
Price to book forward of Monopar Therapeutics Inc – GETTEX:1IY0 - TradingView
Finanzdaten der Monopar Therapeutics Inc-Aktie (MNPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Monopar Therapeutics Inc-Aktie (MNPR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Vu Quan Anh | Chief Financial Officer |
Dec 26 '25 |
Buy |
69.95 |
1,500 |
104,925 |
1,500 |
0.80%
2.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):